OFFSET OF ACTIONS OF ANGIOTENSIN-II, ANGIOTENSIN III, AND THEIR ANALOG ANTAGONISTS IN RENAL AND FEMORAL VASCULAR BEDS - FURTHER EVIDENCE FOR DIFFERENT VASCULAR ANGIOTENSIN RECEPTORS

Half-time of the offset of antagonist action was used to assess the possibility that factors which determine the duration of action of angiotensin antagonists were responsible for regional differences in their effectiveness: thus, for example, enhanced degradation of angiotensin III analogues in the limb circulation would reduce their effectiveness there despite an angiotensin receptor identical to that in the kidney. In the anesthetized dog blood flow in the renal and femoral vascular beds was measured with an electromagnetic flowmeter; the octapeptide analogue saralasin (1-Sar, 8-Ala AII) and a heptapeptide analogue (des-Asp, 8-Ile AII) were infused intravenously (1 μg/kg/min) for 10 minutes and, after stopping the infusion, the effectiveness of their blockade of angiotensin II was assessed over time. The half-time of offset of the antagonist action was determined from semilogarithmic plots of percent inhibition during recovery. Offset of heptapeptide-induced inhibition in the hindlimb would have been more rapid if increased rate of degradation was the explanation for its reduced effectiveness and such was not the case: Indeed offset was more rapid in the renal (5.8 ± 1.1 min) than the femoral vascular bed (11.7 ± 2.1 min) (p > 0.05). Saralasin showed identical offsets in the two beds (renal 17.2 ± 1.5 min; femoral 15.1 ± 2.9 min) (p > 0.5). Consistent with these observations, the offset of the agonist action of angiotensin III was shorter in the kidney (0.69 ± 0.06 min) than in the limb (1.46 ± 0.13 min; p < 0.001). This study has confirmed the relatively greater efficacy of heptapeptide analogues in the renal than in the femoral vascular bed and has ruled out degradation as accounting for that difference: The difference is most likely to lie in a different angiotensin receptor in the two regions. © 1979.